An explainer on pill-form peptide drugs, noting that only a small share of each dose actually gets absorbed by the body.
Recap by typeshit. Full story at Miami Herald on MSN.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
The interim policy, reported by AP, would shield some pharmacies from enforcement over restricted peptides. FDA had flagged risks like contamination and tumor growth.
A propensity-matched analysis looks at whether GLP-1 receptor agonist use tracks with cancer incidence and overall survival in bladder and renal cell carcinoma.
Loading…